ID   PDIA1_HUMAN             Reviewed;         508 AA.
AC   P07237; B2RDQ2; P30037; P32079; Q15205; Q6LDE5;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 3.
DT   10-MAY-2017, entry version 224.
DE   RecName: Full=Protein disulfide-isomerase;
DE            Short=PDI;
DE            EC=5.3.4.1;
DE   AltName: Full=Cellular thyroid hormone-binding protein;
DE   AltName: Full=Prolyl 4-hydroxylase subunit beta;
DE   AltName: Full=p55;
DE   Flags: Precursor;
GN   Name=P4HB; Synonyms=ERBA2L, PDI, PDIA1, PO4DB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3034602;
RA   Pihlajaniemi T., Helaakoski T., Tasanen K., Myllylae R.,
RA   Huhtala M.-L., Koivu J., Kivirikko K.I.;
RT   "Molecular cloning of the beta-subunit of human prolyl 4-hydroxylase.
RT   This subunit and protein disulphide isomerase are products of the same
RT   gene.";
RL   EMBO J. 6:643-649(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3611107;
RA   Cheng S.-Y., Gong Q.-H., Parkison C., Robinson E.A., Appella E.,
RA   Merlino G.T., Pastan I.;
RT   "The nucleotide sequence of a human cellular thyroid hormone binding
RT   protein present in endoplasmic reticulum.";
RL   J. Biol. Chem. 262:11221-11227(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=2846539;
RA   Tasanen K., Parkkonen T., Chow L.T., Kivirikko K.I., Pihlajaniemi T.;
RT   "Characterization of the human gene for a polypeptide that acts both
RT   as the beta subunit of prolyl 4-hydroxylase and as protein disulfide
RT   isomerase.";
RL   J. Biol. Chem. 263:16218-16224(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon, Lung, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24.
RX   PubMed=1597478;
RA   Tasanen K., Oikarinen J., Kivirikko K.I., Pihlajaniemi T.;
RT   "Promoter of the gene for the multifunctional protein disulfide
RT   isomerase polypeptide. Functional significance of the six CCAAT boxes
RT   and other promoter elements.";
RL   J. Biol. Chem. 267:11513-11519(1992).
RN   [8]
RP   PROTEIN SEQUENCE OF 18-41.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [9]
RP   PROTEIN SEQUENCE OF 18-30.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [10]
RP   PROTEIN SEQUENCE OF 18-29.
RC   TISSUE=Liver;
RA   Frutiger S., Hughes G.J.;
RL   Submitted (FEB-1996) to UniProtKB.
RN   [11]
RP   PROTEIN SEQUENCE OF 18-26.
RX   PubMed=2079031; DOI=10.1002/elps.1150111019;
RA   Ward L.D., Hong J., Whitehead R.H., Simpson R.J.;
RT   "Development of a database of amino acid sequences for human colon
RT   carcinoma proteins separated by two-dimensional polyacrylamide gel
RT   electrophoresis.";
RL   Electrophoresis 11:883-891(1990).
RN   [12]
RP   PRELIMINARY PROTEIN SEQUENCE OF 19-28.
RC   TISSUE=Liver;
RX   PubMed=1286669; DOI=10.1002/elps.11501301201;
RA   Hochstrasser D.F., Frutiger S., Paquet N., Bairoch A., Ravier F.,
RA   Pasquali C., Sanchez J.-C., Tissot J.-D., Bjellqvist B., Vargas R.,
RA   Appel R.D., Hughes G.J.;
RT   "Human liver protein map: a reference database established by
RT   microsequencing and gel comparison.";
RL   Electrophoresis 13:992-1001(1992).
RN   [13]
RP   PROTEIN SEQUENCE OF 19-28.
RX   PubMed=9399589; DOI=10.1093/oxfordjournals.jbchem.a021830;
RA   Urade R., Oda T., Ito H., Moriyama T., Utsumi S., Kito M.;
RT   "Functions of characteristic Cys-Gly-His-Cys (CGHC) and Gln-Glu-Asp-
RT   Leu (QEDL) motifs of microsomal ER-60 protease.";
RL   J. Biochem. 122:834-842(1997).
RN   [14]
RP   PROTEIN SEQUENCE OF 201-207; 223-230; 286-308 AND 402-409, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 293-508.
RX   PubMed=3342239; DOI=10.1016/0167-4781(88)90080-2;
RA   Morris J.I., Varandani P.T.;
RT   "Characterization of a cDNA for human glutathione-insulin
RT   transhydrogenase (protein-disulfide isomerase/oxidoreductase).";
RL   Biochim. Biophys. Acta 949:169-180(1988).
RN   [16]
RP   PROTEIN SEQUENCE OF 317-325; 350-369 AND 401-419.
RX   PubMed=1699755; DOI=10.1002/elps.1150110703;
RA   Bauw G., Rasmussen H.H., van den Bulcke M., van Damme J., Puype M.,
RA   Gesser B., Celis J.E., Vandekerckhove J.;
RT   "Two-dimensional gel electrophoresis, protein electroblotting and
RT   microsequencing: a direct link between proteins and genes.";
RL   Electrophoresis 11:528-536(1990).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=10636893; DOI=10.1074/jbc.275.3.1920;
RA   Mezghrani A., Courageot J., Mani J.-C., Pugniere M., Bastiani P.,
RA   Miquelis R.;
RT   "Protein-disulfide isomerase (PDI) in FRTL5 cells. pH-dependent
RT   thyroglobulin/PDI interactions determine a novel PDI function in the
RT   post-endoplasmic reticulum of thyrocytes.";
RL   J. Biol. Chem. 275:1920-1929(2000).
RN   [18]
RP   INTERACTION WITH ERO1B.
RX   PubMed=11707400; DOI=10.1093/emboj/20.22.6288;
RA   Mezghrani A., Fassio A., Benham A., Simmen T., Braakman I., Sitia R.;
RT   "Manipulation of oxidative protein folding and PDI redox state in
RT   mammalian cells.";
RL   EMBO J. 20:6288-6296(2001).
RN   [19]
RP   REDUCTION OF HIV-1 SURFACE PROTEIN GP120 DISULFIDE BONDS, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=11181151; DOI=10.1086/318823;
RA   Fenouillet E., Barbouche R., Courageot J., Miquelis R.;
RT   "The catalytic activity of protein disulfide isomerase is involved in
RT   human immunodeficiency virus envelope-mediated membrane fusion after
RT   CD4 cell binding.";
RL   J. Infect. Dis. 183:744-752(2001).
RN   [20]
RP   FUNCTION.
RX   PubMed=12485997; DOI=10.1093/emboj/cdf685;
RA   Lumb R.A., Bulleid N.J.;
RT   "Is protein disulfide isomerase a redox-dependent molecular
RT   chaperone?";
RL   EMBO J. 21:6763-6770(2002).
RN   [21]
RP   INTERACTION WITH UBQLN1.
RX   PubMed=12095988; DOI=10.1074/jbc.M203412200;
RA   Ko H.S., Uehara T., Nomura Y.;
RT   "Role of ubiquilin associated with protein-disulfide isomerase in the
RT   endoplasmic reticulum in stress-induced apoptotic cell death.";
RL   J. Biol. Chem. 277:35386-35392(2002).
RN   [22]
RP   REDUCTION OF HIV-1 SURFACE PROTEIN GP120 DISULFIDE BONDS.
RX   PubMed=12218051; DOI=10.1074/jbc.M204547200;
RA   Gallina A., Hanley T.M., Mandel R., Trahey M., Broder C.C.,
RA   Viglianti G.A., Ryser H.J.;
RT   "Inhibitors of protein-disulfide isomerase prevent cleavage of
RT   disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1
RT   entry.";
RL   J. Biol. Chem. 277:50579-50588(2002).
RN   [23]
RP   REDUCTION OF HIV-1 SURFACE PROTEIN GP120 DISULFIDE BONDS.
RX   PubMed=12218052; DOI=10.1074/jbc.M205467200;
RA   Barbouche R., Miquelis R., Jones I.M., Fenouillet E.;
RT   "Protein-disulfide isomerase-mediated reduction of two disulfide bonds
RT   of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is
RT   required for fusion.";
RL   J. Biol. Chem. 278:3131-3136(2003).
RN   [24]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=12643545; DOI=10.1021/pr025562r;
RA   Basrur V., Yang F., Kushimoto T., Higashimoto Y., Yasumoto K.,
RA   Valencia J., Muller J., Vieira W.D., Watabe H., Shabanowitz J.,
RA   Hearing V.J., Hunt D.F., Appella E.;
RT   "Proteomic analysis of early melanosomes: identification of novel
RT   melanosomal proteins.";
RL   J. Proteome Res. 2:69-79(2003).
RN   [25]
RP   REVIEW.
RX   PubMed=15158710; DOI=10.1016/j.bbapap.2004.02.017;
RA   Wilkinson B., Gilbert H.F.;
RT   "Protein disulfide isomerase.";
RL   Biochim. Biophys. Acta 1699:35-44(2004).
RN   [26]
RP   REDUCTION OF HIV-1 SURFACE PROTEIN GP120 DISULFIDE BONDS.
RX   PubMed=14592831; DOI=10.1182/blood-2003-05-1390;
RA   Markovic I., Stantchev T.S., Fields K.H., Tiffany L.J., Tomic M.,
RA   Weiss C.D., Broder C.C., Strebel K., Clouse K.A.;
RT   "Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1
RT   envelope-mediated T-cell fusion during viral entry.";
RL   Blood 103:1586-1594(2004).
RN   [27]
RP   REDUCTION OF HIV-1 SURFACE PROTEIN GP120 DISULFIDE BONDS.
RX   PubMed=15644496; DOI=10.1124/mol.104.008276;
RA   Barbouche R., Lortat-Jacob H., Jones I.M., Fenouillet E.;
RT   "Glycosaminoglycans and protein disulfide isomerase-mediated reduction
RT   of HIV Env.";
RL   Mol. Pharmacol. 67:1111-1118(2005).
RN   [28]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION AS RECEPTOR FOR LGALS9,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=21670307; DOI=10.1073/pnas.1017954108;
RA   Bi S., Hong P.W., Lee B., Baum L.G.;
RT   "Galectin-9 binding to cell surface protein disulfide isomerase
RT   regulates the redox environment to enhance T-cell migration and HIV
RT   entry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:10650-10655(2011).
RN   [31]
RP   INTERACTION WITH MTTP, AND SUBCELLULAR LOCATION.
RX   PubMed=23475612; DOI=10.1194/jlr.M031658;
RA   Khatun I., Walsh M.T., Hussain M.M.;
RT   "Loss of both phospholipid and triglyceride transfer activities of
RT   microsomal triglyceride transfer protein in abetalipoproteinemia.";
RL   J. Lipid Res. 54:1541-1549(2013).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [33]
RP   PHOSPHORYLATION AT SER-357.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [34]
RP   INVOLVEMENT IN CLCRP1, VARIANT CLCRP1 CYS-393, AND CHARACTERIZATION OF
RP   VARIANT CLCRP1 CYS-393.
RX   PubMed=25683117; DOI=10.1016/j.ajhg.2014.12.027;
RA   Rauch F., Fahiminiya S., Majewski J., Carrot-Zhang J., Boudko S.,
RA   Glorieux F., Mort J.S., Baechinger H.P., Moffatt P.;
RT   "Cole-Carpenter syndrome is caused by a heterozygous missense mutation
RT   in P4HB.";
RL   Am. J. Hum. Genet. 96:425-431(2015).
RN   [35]
RP   INTERACTION WITH MTTP.
RX   PubMed=26224785; DOI=10.1161/CIRCGENETICS.115.001106;
RA   Walsh M.T., Iqbal J., Josekutty J., Soh J., Di Leo E., Oezaydin E.,
RA   Guenduez M., Tarugi P., Hussain M.M.;
RT   "A novel abetalipoproteinemia missense mutation highlights the
RT   importance of N-Terminal beta-barrel in microsomal triglyceride
RT   transfer protein function.";
RL   Circ. Cardiovasc. Genet. 8:677-687(2015).
RN   [36]
RP   CLEAVAGE OF SIGNAL PEPTIDE [LARGE SCALE ANALYSIS] AFTER ALA-17, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [37]
RP   STRUCTURE BY NMR OF 18-137.
RX   PubMed=8580850; DOI=10.1002/pro.5560041216;
RA   Kemmink J., Darby N.J., Dijkstra K., Scheek R.M., Creighton T.E.;
RT   "Nuclear magnetic resonance characterization of the N-terminal
RT   thioredoxin-like domain of protein disulfide isomerase.";
RL   Protein Sci. 4:2587-2593(1995).
RN   [38]
RP   STRUCTURE BY NMR OF 18-137, AND DISULFIDE BOND.
RX   PubMed=8672469; DOI=10.1021/bi960335m;
RA   Kemmink J., Darby N.J., Dijkstra K., Nilges M., Creighton T.E.;
RT   "Structure determination of the N-terminal thioredoxin-like domain of
RT   protein disulfide isomerase using multidimensional heteronuclear
RT   13C/15N NMR spectroscopy.";
RL   Biochemistry 35:7684-7691(1996).
RN   [39]
RP   STRUCTURE BY NMR OF 136-245.
RX   PubMed=10383197; DOI=10.1023/A:1008341820489;
RA   Kemmink J., Dijkstra K., Mariani M., Scheek R.M., Penka E., Nilges M.,
RA   Darby N.J.;
RT   "The structure in solution of the B domain of protein disulfide
RT   isomerase.";
RL   J. Biomol. NMR 13:357-368(1999).
RN   [40]
RP   STRUCTURE BY NMR OF 368-477.
RG   RIKEN structural genomics initiative (RSGI);
RT   "The solution structure of the second thioredoxin-like domain of human
RT   protein disulfide-isomerase.";
RL   Submitted (NOV-2005) to the PDB data bank.
CC   -!- FUNCTION: This multifunctional protein catalyzes the formation,
CC       breakage and rearrangement of disulfide bonds. At the cell
CC       surface, seems to act as a reductase that cleaves disulfide bonds
CC       of proteins attached to the cell. May therefore cause structural
CC       modifications of exofacial proteins. Inside the cell, seems to
CC       form/rearrange disulfide bonds of nascent proteins. At high
CC       concentrations, functions as a chaperone that inhibits aggregation
CC       of misfolded proteins. At low concentrations, facilitates
CC       aggregation (anti-chaperone activity). May be involved with other
CC       chaperones in the structural modification of the TG precursor in
CC       hormone biogenesis. Also acts a structural subunit of various
CC       enzymes such as prolyl 4-hydroxylase and microsomal
CC       triacylglycerol transfer protein MTTP. Receptor for LGALS9; the
CC       interaction retains P4HB at the cell surface of Th2 T helper
CC       cells, increasing disulfide reductase activity at the plasma
CC       membrane, altering the plasma membrane redox state and enhancing
CC       cell migration (PubMed:21670307). {ECO:0000269|PubMed:10636893,
CC       ECO:0000269|PubMed:12485997, ECO:0000269|PubMed:21670307}.
CC   -!- CATALYTIC ACTIVITY: Catalyzes the rearrangement of -S-S- bonds in
CC       proteins.
CC   -!- SUBUNIT: Heterodimer; heterodimerizes with the protein microsomal
CC       triglyceride transfer MTTP (PubMed:23475612, PubMed:26224785).
CC       Homodimer. Monomers and homotetramers may also occur. Also
CC       constitutes the structural subunit of prolyl 4-hydroxylase and of
CC       the microsomal triacylglycerol transfer protein MTTP in mammalian
CC       cells. Stabilizes both enzymes and retain them in the ER without
CC       contributing to the catalytic activity (By similarity). Binds
CC       UBQLN1 (PubMed:12095988). Interacts with ERO1B (PubMed:11707400).
CC       Binds to CD4, and upon HIV-1 binding to the cell membrane, is part
CC       of a P4HB/PDI-CD4-CXCR4-gp120 complex. {ECO:0000250,
CC       ECO:0000269|PubMed:11707400, ECO:0000269|PubMed:12095988,
CC       ECO:0000269|PubMed:23475612, ECO:0000269|PubMed:26224785}.
CC   -!- INTERACTION:
CC       Q96HE7:ERO1A; NbExp=2; IntAct=EBI-395883, EBI-2564539;
CC       Q8TCT9:HM13; NbExp=3; IntAct=EBI-395883, EBI-347472;
CC       Q13162:PRDX4; NbExp=2; IntAct=EBI-395883, EBI-2211957;
CC       Q03518:TAP1; NbExp=4; IntAct=EBI-395883, EBI-747259;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum
CC       {ECO:0000269|PubMed:23475612}. Endoplasmic reticulum lumen
CC       {ECO:0000269|PubMed:10636893, ECO:0000269|PubMed:23475612}.
CC       Melanosome {ECO:0000269|PubMed:12643545,
CC       ECO:0000269|PubMed:17081065}. Cell membrane
CC       {ECO:0000269|PubMed:21670307}; Peripheral membrane protein
CC       {ECO:0000305}. Note=Highly abundant. In some cell types, seems to
CC       be also secreted or associated with the plasma membrane, where it
CC       undergoes constant shedding and replacement from intracellular
CC       sources (Probable). Localizes near CD4-enriched regions on
CC       lymphoid cell surfaces (PubMed:11181151). Identified by mass
CC       spectrometry in melanosome fractions from stage I to stage IV
CC       (PubMed:10636893). Colocalizes with MTTP in the endoplasmic
CC       reticulum (PubMed:23475612). {ECO:0000269|PubMed:10636893,
CC       ECO:0000269|PubMed:11181151, ECO:0000269|PubMed:23475612,
CC       ECO:0000305}.
CC   -!- DISEASE: Cole-Carpenter syndrome 1 (CLCRP1) [MIM:112240]: A form
CC       of Cole-Carpenter syndrome, a disorder characterized by features
CC       of osteogenesis imperfecta such as bone deformities and severe
CC       bone fragility with frequent fractures, in association with
CC       craniosynostosis, ocular proptosis, hydrocephalus, growth failure
CC       and distinctive facial features. Craniofacial findings include
CC       marked frontal bossing, midface hypoplasia, and micrognathia.
CC       Despite the craniosynostosis and hydrocephalus, intellectual
CC       development is normal. CLCRP1 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:25683117}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Reduces and may activate fusogenic properties of
CC       HIV-1 gp120 surface protein, thereby enabling HIV-1 entry into the
CC       cell.
CC   -!- SIMILARITY: Belongs to the protein disulfide isomerase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X05130; CAA28775.1; -; mRNA.
DR   EMBL; J02783; AAA61169.1; -; mRNA.
DR   EMBL; M22806; AAC13652.1; -; Genomic_DNA.
DR   EMBL; M22803; AAC13652.1; JOINED; Genomic_DNA.
DR   EMBL; M22804; AAC13652.1; JOINED; Genomic_DNA.
DR   EMBL; M22805; AAC13652.1; JOINED; Genomic_DNA.
DR   EMBL; AK315631; BAG37999.1; -; mRNA.
DR   EMBL; CH471099; EAW89690.1; -; Genomic_DNA.
DR   EMBL; BC010859; AAH10859.1; -; mRNA.
DR   EMBL; BC029617; AAH29617.1; -; mRNA.
DR   EMBL; BC071892; AAH71892.1; -; mRNA.
DR   EMBL; S37207; AAB22262.2; -; Genomic_DNA.
DR   EMBL; X07077; CAA30112.1; -; mRNA.
DR   CCDS; CCDS11787.1; -.
DR   PIR; A31913; ISHUSS.
DR   RefSeq; NP_000909.2; NM_000918.3.
DR   UniGene; Hs.464336; -.
DR   PDB; 1BJX; NMR; -; A=136-245.
DR   PDB; 1MEK; NMR; -; A=18-137.
DR   PDB; 1X5C; NMR; -; A=368-475.
DR   PDB; 2BJX; NMR; -; A=136-245.
DR   PDB; 2K18; NMR; -; A=135-357.
DR   PDB; 3BJ5; X-ray; 2.20 A; A=230-368.
DR   PDB; 3UEM; X-ray; 2.29 A; A=137-479.
DR   PDB; 4EKZ; X-ray; 2.51 A; A=18-479.
DR   PDB; 4EL1; X-ray; 2.88 A; A/B=18-479.
DR   PDB; 4JU5; X-ray; 2.28 A; A/B=135-367.
DR   PDBsum; 1BJX; -.
DR   PDBsum; 1MEK; -.
DR   PDBsum; 1X5C; -.
DR   PDBsum; 2BJX; -.
DR   PDBsum; 2K18; -.
DR   PDBsum; 3BJ5; -.
DR   PDBsum; 3UEM; -.
DR   PDBsum; 4EKZ; -.
DR   PDBsum; 4EL1; -.
DR   PDBsum; 4JU5; -.
DR   ProteinModelPortal; P07237; -.
DR   SMR; P07237; -.
DR   BioGrid; 111073; 129.
DR   DIP; DIP-32979N; -.
DR   IntAct; P07237; 65.
DR   MINT; MINT-4999403; -.
DR   STRING; 9606.ENSP00000327801; -.
DR   BindingDB; P07237; -.
DR   ChEMBL; CHEMBL5422; -.
DR   DrugBank; DB03615; Ribostamycin.
DR   iPTMnet; P07237; -.
DR   PhosphoSitePlus; P07237; -.
DR   SwissPalm; P07237; -.
DR   BioMuta; P4HB; -.
DR   DMDM; 2507460; -.
DR   DOSAC-COBS-2DPAGE; P07237; -.
DR   OGP; P07237; -.
DR   REPRODUCTION-2DPAGE; IPI00010796; -.
DR   REPRODUCTION-2DPAGE; P07237; -.
DR   SWISS-2DPAGE; P07237; -.
DR   EPD; P07237; -.
DR   MaxQB; P07237; -.
DR   PaxDb; P07237; -.
DR   PeptideAtlas; P07237; -.
DR   PRIDE; P07237; -.
DR   TopDownProteomics; P07237; -.
DR   DNASU; 5034; -.
DR   Ensembl; ENST00000331483; ENSP00000327801; ENSG00000185624.
DR   GeneID; 5034; -.
DR   KEGG; hsa:5034; -.
DR   UCSC; uc002kbn.2; human.
DR   CTD; 5034; -.
DR   DisGeNET; 5034; -.
DR   GeneCards; P4HB; -.
DR   HGNC; HGNC:8548; P4HB.
DR   HPA; CAB012463; -.
DR   HPA; HPA018884; -.
DR   MalaCards; P4HB; -.
DR   MIM; 112240; phenotype.
DR   MIM; 176790; gene.
DR   neXtProt; NX_P07237; -.
DR   OpenTargets; ENSG00000185624; -.
DR   PharmGKB; PA32876; -.
DR   eggNOG; KOG0190; Eukaryota.
DR   eggNOG; COG0526; LUCA.
DR   GeneTree; ENSGT00860000133691; -.
DR   HOGENOM; HOG000162459; -.
DR   HOVERGEN; HBG005920; -.
DR   InParanoid; P07237; -.
DR   KO; K09580; -.
DR   OMA; IEKYVDP; -.
DR   OrthoDB; EOG091G08WM; -.
DR   PhylomeDB; P07237; -.
DR   TreeFam; TF106381; -.
DR   BRENDA; 5.3.4.1; 2681.
DR   Reactome; R-HSA-1650814; Collagen biosynthesis and modifying enzymes.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-3299685; Detoxification of Reactive Oxygen Species.
DR   Reactome; R-HSA-5358346; Hedgehog ligand biogenesis.
DR   Reactome; R-HSA-8866423; VLDL biosynthesis.
DR   ChiTaRS; P4HB; human.
DR   EvolutionaryTrace; P07237; -.
DR   GeneWiki; P4HB; -.
DR   GenomeRNAi; 5034; -.
DR   PMAP-CutDB; P07237; -.
DR   PRO; PR:P07237; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000185624; -.
DR   CleanEx; HS_P4HB; -.
DR   ExpressionAtlas; P07237; baseline and differential.
DR   Genevisible; P07237; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0034663; C:endoplasmic reticulum chaperone complex; IEA:Ensembl.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016222; C:procollagen-proline 4-dioxygenase complex; IDA:MGI.
DR   GO; GO:0019899; F:enzyme binding; IEA:Ensembl.
DR   GO; GO:0005178; F:integrin binding; IPI:UniProtKB.
DR   GO; GO:0015037; F:peptide disulfide oxidoreductase activity; IDA:UniProtKB.
DR   GO; GO:0004656; F:procollagen-proline 4-dioxygenase activity; TAS:ProtInc.
DR   GO; GO:0003756; F:protein disulfide isomerase activity; IDA:CACAO.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0045454; P:cell redox homeostasis; IEA:InterPro.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:BHF-UCL.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; TAS:Reactome.
DR   GO; GO:0018401; P:peptidyl-proline hydroxylation to 4-hydroxy-L-proline; IDA:MGI.
DR   GO; GO:0046598; P:positive regulation of viral entry into host cell; IMP:UniProtKB.
DR   GO; GO:0006457; P:protein folding; IBA:GO_Central.
DR   GO; GO:1902175; P:regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IMP:BHF-UCL.
DR   GO; GO:0000302; P:response to reactive oxygen species; TAS:Reactome.
DR   InterPro; IPR005788; Disulphide_isomerase.
DR   InterPro; IPR005792; Prot_disulphide_isomerase.
DR   InterPro; IPR012336; Thioredoxin-like_fold.
DR   InterPro; IPR017937; Thioredoxin_CS.
DR   InterPro; IPR013766; Thioredoxin_domain.
DR   Pfam; PF00085; Thioredoxin; 2.
DR   SUPFAM; SSF52833; SSF52833; 4.
DR   TIGRFAMs; TIGR01130; ER_PDI_fam; 1.
DR   TIGRFAMs; TIGR01126; pdi_dom; 2.
DR   PROSITE; PS00014; ER_TARGET; 1.
DR   PROSITE; PS00194; THIOREDOXIN_1; 2.
DR   PROSITE; PS51352; THIOREDOXIN_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell membrane; Chaperone;
KW   Complete proteome; Craniosynostosis; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Endoplasmic reticulum; Isomerase;
KW   Membrane; Osteogenesis imperfecta; Phosphoprotein;
KW   Redox-active center; Reference proteome; Repeat; Signal.
FT   SIGNAL        1     17       {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|PubMed:2079031,
FT                                ECO:0000269|PubMed:9150948,
FT                                ECO:0000269|Ref.10}.
FT   CHAIN        18    508       Protein disulfide-isomerase.
FT                                /FTId=PRO_0000034195.
FT   DOMAIN       18    134       Thioredoxin 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00691}.
FT   DOMAIN      349    475       Thioredoxin 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00691}.
FT   MOTIF       505    508       Prevents secretion from ER.
FT   ACT_SITE     53     53       Nucleophile.
FT   ACT_SITE     56     56       Nucleophile.
FT   ACT_SITE    397    397       Nucleophile. {ECO:0000250}.
FT   ACT_SITE    400    400       Nucleophile. {ECO:0000250}.
FT   SITE         54     54       Contributes to redox potential value.
FT   SITE         55     55       Contributes to redox potential value.
FT   SITE        120    120       Lowers pKa of C-terminal Cys of first
FT                                active site.
FT   SITE        398    398       Contributes to redox potential value.
FT                                {ECO:0000250}.
FT   SITE        399    399       Contributes to redox potential value.
FT                                {ECO:0000250}.
FT   SITE        461    461       Lowers pKa of C-terminal Cys of second
FT                                active site. {ECO:0000250}.
FT   MOD_RES     200    200       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P09103}.
FT   MOD_RES     222    222       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P09103}.
FT   MOD_RES     271    271       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P09103}.
FT   MOD_RES     357    357       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   DISULFID     53     56       Redox-active. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00691,
FT                                ECO:0000269|PubMed:8672469}.
FT   DISULFID    397    400       Redox-active. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00691}.
FT   VARIANT     393    393       Y -> C (in CLCRP1; impairs ability to act
FT                                as a disulfide isomerase enzyme;
FT                                dbSNP:rs786204843).
FT                                {ECO:0000269|PubMed:25683117}.
FT                                /FTId=VAR_073440.
FT   CONFLICT     10     11       AV -> PW (in Ref. 1; CAA28775).
FT                                {ECO:0000305}.
FT   CONFLICT     21     21       E -> D (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     24     24       D -> V (in Ref. 13; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     44     45       LL -> PP (in Ref. 1; CAA28775).
FT                                {ECO:0000305}.
FT   CONFLICT     49     49       Y -> H (in Ref. 1; CAA28775).
FT                                {ECO:0000305}.
FT   CONFLICT    141    141       P -> R (in Ref. 2; AAA61169).
FT                                {ECO:0000305}.
FT   CONFLICT    360    362       LPE -> RAG (in Ref. 2; AAA61169).
FT                                {ECO:0000305}.
FT   CONFLICT    372    372       L -> P (in Ref. 2; AAA61169).
FT                                {ECO:0000305}.
FT   CONFLICT    439    439       S -> G (in Ref. 1; CAA28775).
FT                                {ECO:0000305}.
FT   CONFLICT    444    444       K -> G (in Ref. 1; CAA28775).
FT                                {ECO:0000305}.
FT   CONFLICT    460    460       E -> Q (in Ref. 15; CAA30112).
FT                                {ECO:0000305}.
FT   CONFLICT    481    481       D -> V (in Ref. 1; CAA28775).
FT                                {ECO:0000305}.
FT   STRAND       21     23       {ECO:0000244|PDB:4EKZ}.
FT   STRAND       26     28       {ECO:0000244|PDB:4EKZ}.
FT   TURN         31     33       {ECO:0000244|PDB:4EL1}.
FT   HELIX        34     40       {ECO:0000244|PDB:4EKZ}.
FT   STRAND       42     49       {ECO:0000244|PDB:4EKZ}.
FT   HELIX        54     72       {ECO:0000244|PDB:4EKZ}.
FT   STRAND       78     83       {ECO:0000244|PDB:4EKZ}.
FT   TURN         84     86       {ECO:0000244|PDB:4EKZ}.
FT   HELIX        88     93       {ECO:0000244|PDB:4EKZ}.
FT   STRAND      101    106       {ECO:0000244|PDB:4EKZ}.
FT   STRAND      110    112       {ECO:0000244|PDB:4EL1}.
FT   STRAND      114    116       {ECO:0000244|PDB:4EL1}.
FT   HELIX       122    132       {ECO:0000244|PDB:4EKZ}.
FT   STRAND      137    139       {ECO:0000244|PDB:3UEM}.
FT   HELIX       143    151       {ECO:0000244|PDB:4JU5}.
FT   STRAND      153    160       {ECO:0000244|PDB:4JU5}.
FT   TURN        162    165       {ECO:0000244|PDB:1BJX}.
FT   HELIX       167    178       {ECO:0000244|PDB:4JU5}.
FT   STRAND      180    182       {ECO:0000244|PDB:4JU5}.
FT   STRAND      184    187       {ECO:0000244|PDB:4JU5}.
FT   HELIX       190    195       {ECO:0000244|PDB:4JU5}.
FT   STRAND      199    209       {ECO:0000244|PDB:4JU5}.
FT   STRAND      212    215       {ECO:0000244|PDB:4JU5}.
FT   HELIX       222    232       {ECO:0000244|PDB:4JU5}.
FT   STRAND      237    239       {ECO:0000244|PDB:3BJ5}.
FT   TURN        242    244       {ECO:0000244|PDB:3BJ5}.
FT   HELIX       245    249       {ECO:0000244|PDB:3BJ5}.
FT   STRAND      250    252       {ECO:0000244|PDB:3BJ5}.
FT   STRAND      255    260       {ECO:0000244|PDB:3BJ5}.
FT   STRAND      265    267       {ECO:0000244|PDB:3BJ5}.
FT   HELIX       268    280       {ECO:0000244|PDB:3BJ5}.
FT   TURN        281    285       {ECO:0000244|PDB:3BJ5}.
FT   STRAND      287    291       {ECO:0000244|PDB:3BJ5}.
FT   HELIX       296    298       {ECO:0000244|PDB:3BJ5}.
FT   HELIX       299    304       {ECO:0000244|PDB:3BJ5}.
FT   HELIX       309    311       {ECO:0000244|PDB:3BJ5}.
FT   STRAND      313    319       {ECO:0000244|PDB:3BJ5}.
FT   STRAND      321    323       {ECO:0000244|PDB:3BJ5}.
FT   STRAND      325    327       {ECO:0000244|PDB:3BJ5}.
FT   STRAND      330    332       {ECO:0000244|PDB:4EKZ}.
FT   HELIX       336    347       {ECO:0000244|PDB:3BJ5}.
FT   STRAND      353    355       {ECO:0000244|PDB:3BJ5}.
FT   HELIX       362    364       {ECO:0000244|PDB:3BJ5}.
FT   STRAND      367    372       {ECO:0000244|PDB:3UEM}.
FT   TURN        374    376       {ECO:0000244|PDB:3UEM}.
FT   HELIX       377    381       {ECO:0000244|PDB:3UEM}.
FT   STRAND      387    393       {ECO:0000244|PDB:3UEM}.
FT   HELIX       398    413       {ECO:0000244|PDB:3UEM}.
FT   TURN        414    416       {ECO:0000244|PDB:3UEM}.
FT   STRAND      418    426       {ECO:0000244|PDB:3UEM}.
FT   TURN        427    429       {ECO:0000244|PDB:3UEM}.
FT   STRAND      439    446       {ECO:0000244|PDB:3UEM}.
FT   STRAND      448    451       {ECO:0000244|PDB:3UEM}.
FT   HELIX       463    470       {ECO:0000244|PDB:3UEM}.
FT   TURN        471    473       {ECO:0000244|PDB:3UEM}.
SQ   SEQUENCE   508 AA;  57116 MW;  906CE6D9900B8FCE CRC64;
     MLRRALLCLA VAALVRADAP EEEDHVLVLR KSNFAEALAA HKYLLVEFYA PWCGHCKALA
     PEYAKAAGKL KAEGSEIRLA KVDATEESDL AQQYGVRGYP TIKFFRNGDT ASPKEYTAGR
     EADDIVNWLK KRTGPAATTL PDGAAAESLV ESSEVAVIGF FKDVESDSAK QFLQAAEAID
     DIPFGITSNS DVFSKYQLDK DGVVLFKKFD EGRNNFEGEV TKENLLDFIK HNQLPLVIEF
     TEQTAPKIFG GEIKTHILLF LPKSVSDYDG KLSNFKTAAE SFKGKILFIF IDSDHTDNQR
     ILEFFGLKKE ECPAVRLITL EEEMTKYKPE SEELTAERIT EFCHRFLEGK IKPHLMSQEL
     PEDWDKQPVK VLVGKNFEDV AFDEKKNVFV EFYAPWCGHC KQLAPIWDKL GETYKDHENI
     VIAKMDSTAN EVEAVKVHSF PTLKFFPASA DRTVIDYNGE RTLDGFKKFL ESGGQDGAGD
     DDDLEDLEEA EEPDMEEDDD QKAVKDEL
//
